Devonian Welcomes Viktoria Krasteva as New CFO
Devonian Health Group Inc. (“Devonian”) (TSXV: GSD; OTCQB: DVHGF), a company dedicated to innovative solutions for inflammatory diseases, is pleased to announce the appointment of Ms. Viktoria Krasteva as its new Chief Financial Officer. With her extensive background in financial leadership, Ms. Krasteva steps into a pivotal role as part of the company's corporate leadership team.
Leadership Transition and Growth Plans
Starting in her new position, Ms. Krasteva will replace Ms. Colette Laurin, who has served as interim CFO. Laurin has graciously agreed to assist with the transition to ensure a seamless shift as Devonian continues to evolve. The company is in a dynamic phase, actively focusing on broader market opportunities and advancing its strategic objectives.
Luc Gregoire, the Chief Executive Officer of Devonian, expressed his enthusiasm, stating, "We are excited to have Viktoria joining Devonian at such a pivotal stage of our growth. Her impressive track record in financial and strategic leadership will be invaluable as we navigate through this important next phase of our journey."
Expertise in Financial Management
Ms. Krasteva brings an impressive 20-year history in financial management across varied sectors, including life sciences, digital media, and online services. As a chartered professional accountant (CPA), she possesses a strong foundation in both private and public financial markets. Her educational background includes a bachelor’s degree in international commerce from the University of World Economy in Bulgaria, coupled with graduate degrees in Public Accountancy from Concordia and McGill Universities.
Reflecting on her new role, Ms. Krasteva stated, "I am inspired and thrilled to be joining the Devonian team at such a critical juncture of opportunity for the Corporation. I look forward to leveraging my experience to help us reach the next level of success."
About Devonian Health Group Inc.
Devonian Health Group Inc. is at the forefront of clinical stage pharmaceutical development, with a strong commitment to addressing inflammatory autoimmune conditions through innovative and therapeutic advancements. The company’s mission focuses on creating prescription drugs that specifically target unmet medical needs, such as ulcerative colitis and atopic dermatitis.
With a robust foundation of over 15 years of research, Devonian is strategically positioned to expedite drug development, supported by regulatory guidelines from the U.S. Food and Drug Administration that favor more efficient pathways for botanical prescription drugs compared to traditional methods.
Innovative Cosmeceutical Ventures
In addition to its pharmaceutical pursuits, Devonian is actively working on high-value cosmeceutical products, utilizing the same proprietary approaches that underline its pharmaceutical innovations. The company also operates Altius Healthcare Inc., a subsidiary focused on the commercialization of prescription pharmaceutical products in Canada under various licenses from established pharmaceutical companies.
A Bright Future Ahead
Incorporated in 2015, Devonian is headquartered in Québec and boasts a state-of-the-art extraction facility ensuring full traceability ‘from the seed to the pill’. The company is listed on the TSX Venture Exchange (TSXV: GSD) and the OTCQB exchange (OTCQB: DVHGF), emphasizing its commitment to transparency and growth in the evolving healthcare landscape.
Frequently Asked Questions
What is the new role of Viktoria Krasteva at Devonian?
Viktoria Krasteva has been appointed as the Chief Financial Officer (CFO) of Devonian Health Group Inc.
What experience does Viktoria Krasteva bring to Devonian?
Ms. Krasteva has 20 years of financial management experience and is a chartered professional accountant with a strong background in various industries.
What is Devonian Health Group Inc. focusing on?
Devonian is focused on developing unique solutions for inflammatory diseases and also ventures into cosmeceutical product development.
Where is Devonian headquartered?
Devonian is headquartered in Québec and runs a state-of-the-art extraction facility.
When will Viktoria Krasteva officially start her role?
She is scheduled to begin her role as CFO on February 17, 2025.
